DCPH - Deciphera Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.92
-0.83 (-2.89%)
As of 12:32PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close28.75
Open28.62
Bid27.86 x 800
Ask27.96 x 1800
Day's Range27.54 - 28.91
52 Week Range15.15 - 45.61
Volume179,108
Avg. Volume171,967
Market Cap1.051B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.73
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.00
Trade prices are not sourced from all markets
  • Business Wire22 days ago

    Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00 PM ET at the InterContinental New York Barclay Hotel. Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.

  • GlobeNewswire29 days ago

    Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has appointed Daniel C. Martin as Chief Commercial Officer. In this newly created role, Mr. Martin will be responsible for establishing the global strategy and leading the commercial organization at Deciphera. “We are excited to welcome Dan to the Deciphera leadership team as we continue to build the capabilities necessary to become a fully-integrated biopharmaceutical company,” said Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera Pharmaceuticals.

  • Benzinga2 months ago

    Why Raymond James Is Bullish On Deciphera, Dova Pharmaceuticals

    Raymond James launched coverage of two pharmaceutical names Tuesday afternoon with bullish ratings. Raymond James' Laura Chico initiated coverage of Deciphera Pharmaceuticals with an Outperform rating and $47 price target.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind CIRCOR International, Duluth, Griffon, Despegar, SEACOR, and Deciphera Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CIRCOR ...

  • Business Wire2 months ago

    Deciphera Pharmaceuticals, Inc. to Participate in Citi’s 13th Annual Biotech Conference

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will participate in a panel discussion on targeted therapies in oncology at Citi’s 13th Annual Biotech Conference on Wednesday, September 5, 2018 at 3:15 PM ET at the Four Seasons Hotel Boston. Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.

  • Business Wire2 months ago

    Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results

    - Presented Data at 2018 ASCO Annual Meeting Supporting Potential for DCC-2618 in Second-Line GIST Patients -

  • Business Wire3 months ago

    Deciphera Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018 at 3:30 PM ET at the InterContinental Boston Hotel. Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within Xylem, Duluth, Deciphera Pharmaceuticals, Mesabi Trust, Associated Banc-Corp, and AG Mortgage Investment Trust — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, July 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Xylem ...

  • 3 Top Stocks That Aren't on Wall Street's Radar
    Motley Fool3 months ago

    3 Top Stocks That Aren't on Wall Street's Radar

    You can buy these three surprising companies before Wall Street catches on. It could pay off with huge returns, too.

  • Business Wire4 months ago

    Deciphera Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced underwritten public offering, which closed on June 11, 2018, have exercised in full their option to purchase an additional 645,000 shares of Deciphera’s common stock. Including this option exercise, total gross proceeds to Deciphera from the offering of an aggregate 4,945,000 shares at a public offering price of $40.00 per share will be approximately $198 million, before deducting the underwriting discounts and commissions and other offering expenses. Canaccord Genuity LLC and JMP Securities LLC acted as lead managers, and Nomura Securities International, Inc. and Raymond James & Associates, Inc. acted as co-managers for the offering.

  • Benzinga4 months ago

    Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain

    Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) lost a sell-side bull Tuesday, with a B. Riley FBR analyst praising the company's pipeline but concluding the biotech's positives are priced into the stock. ...

  • Business Wire4 months ago

    Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the JMP Securities 2018 Life Sciences Conference on Wednesday, June 20, 2018 at 8:30 AM ET at the St. Regis in New York. Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 11) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...

  • Business Wire4 months ago

    Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $40.00 per share for aggregate gross proceeds of $172 million, before deducting underwriting discounts and commissions and estimated offering expenses. Canaccord Genuity LLC and JMP Securities LLC acted as lead managers, and Nomura Securities International, Inc. and Raymond James & Associates, Inc. acted as co-managers for the offering.

  • Here's Why Deciphera Pharmaceuticals Fell as Much as 11.9% Today
    Motley Fool4 months ago

    Here's Why Deciphera Pharmaceuticals Fell as Much as 11.9% Today

    The company is taking advantage of a recent surge in the stock price to raise growth capital.

  • Business Wire4 months ago

    Deciphera Pharmaceuticals Announces Pricing of Public Offering

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of an underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $40.00 per share for aggregate gross proceeds of $172 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock are being offered by Deciphera. In addition, Deciphera granted the underwriters a 30-day option to purchase up to 645,000 additional shares of its common stock.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Stocks to Watch: Deciphera Pharmaceuticals and Jounce Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 5, 2018 / While shares of Deciphera skyrocketed yesterday and hit a new high on positive data results, shares of Jounce Therapeutics saw the opposite result on its own ...

  • Business Wire4 months ago

    Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has commenced a proposed public offering of 3,750,000 in shares of its common stock. J.P. Morgan and Piper Jaffray are acting as joint book-running managers for the offering. A registration statement relating to the offering has been filed with the Securities and Exchange Commission but has not yet become effective.

  • Business Wire5 months ago

    Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618

    Deciphera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated data from its ongoing Phase 1 clinical trial of DCC-2618, the company’s broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors at the American Society of Clinical Oncology Annual Meeting ...

  • Business Wire5 months ago

    Deciphera Pharmaceuticals Appoints Stephen B. Ruddy, Ph.D. as Chief Technical Officer

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has appointed Stephen B. Ruddy, Ph.D. as Chief Technical Officer. In this newly created role, Dr. Ruddy will be responsible for establishing and leading a world-class manufacturing and supply chain organization at Deciphera. “We are pleased to add Steve to our leadership team at this strategically important time in the evolution of Deciphera," said Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera Pharmaceuticals.

  • Business Wire5 months ago

    Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has elected Mr. Steven L. Hoerter, Chief Commercial Officer at Agios Pharmaceuticals, Inc., to its Board of Directors, effective as of May 17, 2018. Mr. Hoerter will serve as an independent director and a member of the Nominating and Corporate Governance Committee. The number of Deciphera directors was increased from eight to nine in connection with Mr. Hoerter’s election.

  • Business Wire5 months ago

    Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

    Deciphera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that member

  • Business Wire5 months ago

    Deciphera Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results

    Deciphera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the first quarter ended March 31, 2018, and provided an update on recent clinical and corporate developments.

  • Business Wire6 months ago

    Preclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents

    Deciphera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced pre-clinical data for DCC-2618 confirming a broad spectrum of potent inhibition across primary and secondary KIT mutations and primary PDGFRα mutations.